PDGFRB mutants found in patients with familial infantile myofibromatosis or overgrowth syndrome are oncogenic and sensitive to imatinib

No abstract is available for this paper.

• Publication year

  2016

• Venue

  Oncogene

• Publication date

  2016-06-23

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1038/onc.2015.383PMID 26455322
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Novel overgrowth syndrome phenotype due to recurrent de novo PDGFRB mutation.

  2015cited by this paper
• Idiopathic basal ganglia calcification-associated PDGFRB mutations impair the receptor signalling

  2014cited by this paper
• Infantile myofibromatosis: a series of 28 cases.

  2014cited by this paper
• Modulation of expressivity in PDGFRB-related infantile myofibromatosis: a role for PTPRG?

  2014cited by this paper
• The tyrosine phosphatase SHP2 is required for cell transformation by the receptor tyrosine kinase mutants FIP1L1‐PDGFRα and PDGFRα D842V

  2014cited by this paper
• Differential Diagnoses of Overgrowth Syndromes: The Most Important Clinical and Radiological Disease Manifestations

  2014cited by this paper
• PDGF receptor signaling networks in normal and cancer cells.

  2014cited by this paper
• PDGFRA alterations in cancer: characterization of a gain-of-function V536E transmembrane mutant as well as loss-of-function and passenger mutations

  2014cited by this paper
• Growth deceleration in children treated with imatinib for chronic myeloid leukaemia.

  2014cited by this paper
• Phenotypic spectrum of probable and genetically-confirmed idiopathic basal ganglia calcification.

  2013cited by this paper
• Targeting the PDGF signaling pathway in tumor treatment

  2013cited by this paper
• Mutation of the PDGFRB gene as a cause of idiopathic basal ganglia calcification

  2013cited by this paper
• A recurrent PDGFRB mutation causes familial infantile myofibromatosis.

  2013cited by this paper
• Mutations in PDGFRB cause autosomal-dominant infantile myofibromatosis.

  2013cited by this paper
• Extracellular assembly and activation principles of oncogenic class III receptor tyrosine kinases

  2012cited by this paper
• Multiple oligomerization domains of KANK1-PDGFRβ are required for JAK2-independent hematopoietic cell proliferation and signaling via STAT5 and ERK

  2011cited by this paper
• Activating ALK mutations found in neuroblastoma are inhibited by Crizotinib and NVP-TAE684.

  2011cited by this paper
• A mosaic activating mutation in AKT1 associated with the Proteus syndrome.

  2011cited by this paper
• Integrating pharmacogenetics and therapeutic drug monitoring: optimal dosing of imatinib as a case-example

  2010cited by this paper
• KANK1, a candidate tumor suppressor gene, is fused to PDGFRB in an imatinib-responsive myeloid neoplasm with severe thrombocythemia

  2010cited by this paper
• Familial occurrence of infantile myofibromatosis

  2010cited by this paper
• New insights into the mechanisms of hematopoietic cell transformation by activated receptor tyrosine kinases.

  2010cited by this paper
• Role of platelet-derived growth factors in physiology and medicine.

  2008cited by this paper
• Durable responses to imatinib in patients with PDGFRB fusion gene-positive and BCR-ABL-negative chronic myeloproliferative disorders.

  2007cited by this paper
• An activating mutation in the PDGF receptor-beta causes abnormal morphology in the mouse placenta.

  2007cited by this paper
• PDGFRA mutations in gastrointestinal stromal tumors: frequency, spectrum and in vitro sensitivity to imatinib.

  2005cited by this paper
• Severe vascular disturbance in a case of familial brain calcinosis

  2005cited by this paper
• Autosomal dominant inheritance of infantile myofibromatosis

  2004cited by this paper
• Infantile myofibromatosis: a case report and review of the literature.

  2004cited by this paper
• A Gain of Function Mutation in the Activation Loop of Plateletderived Growth Factor β-Receptor Deregulates Its Kinase Activity*

  2004cited by this paper
• Autoinhibition of the Platelet-derived Growth Factor β-Receptor Tyrosine Kinase by Its C-terminal Tail*

  2004cited by this paper
• Overgrowth syndromes: is dysfunctional PI3-kinase signalling a unifying mechanism?

  2003cited by this paper
• PDGFRA Activating Mutations in Gastrointestinal Stromal Tumors

  2003cited by this paper
• MAP kinase activation by interleukin-9 in lymphoid and mast cell lines

  2003cited by this paper
• A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome.

  2003cited by this paper
• STAT5 activation is required for interleukin-9-dependent growth and transformation of lymphoid cells.

  2000cited by this paper
• Signal transduction via platelet-derived growth factor receptors.

  1998cited by this paper
• A novel gain-of-function mutation of c-kit gene in gastrointestinal stromal tumors.

  1998cited by this paper
• The PDGF alpha receptor is required for neural crest cell development and for normal patterning of the somites.

  1997cited by this paper
• Abnormal kidney development and hematological disorders in PDGF beta-receptor mutant mice.

  1994cited by this paper
• Platelet-derived growth factor receptor inducibility is acquired immediately after translation and does not require glycosylation.

  1989cited by this paper
• Infantile myofibromatosis.

  1985cited by this paper
• Infantile myofibromatosis

  1981cited by this paper

• Novel PDGFRB Gene Fusions in Two Cases of Infantile Myofibromatosis

  2025cites this paper
• A Distinct Subtype of Uterine Sarcoma: Case Report of a High-Grade Uterine Sarcoma With Myogenic Differentiation Harboring a PDGFRB Hotspot Mutation.

  2025cites this paper
• Recurrent platelet-derived growth factor receptor beta gene mutations in Kosaki overgrowth syndrome: a molecular and clinical overview.

  2025cites this paper
• Variable response of germline activating PDGFRB variants to receptor tyrosine kinase inhibitors: implications for treatment

  2025cites this paper
• Haploinsufficiency of Runx2 restores the cranial sutures in a mouse model of Pdgfrb-related craniosynostosis.

  2025cites this paper
• Congenital myofibromatosis of the porta hepatis: a case report

  2025cites this paper
• Treatment of PDGFRB ‐Related Penttinen Syndrome With Imatinib in a Young Child

  2025cites this paper
• ‘Knowing and Treating Kosaki/Penttinen syndrome’ international collaborative consortium: recommendations for follow-up, natural history and a real-life observational study about safety and efficacy profile of tyrosine kinase inhibitors

  2025cites this paper
• Recurrent PDGFRB Mutations in Pulmonary Microcystic Fibromyxoma: A Clinicopathologic and Molecular Analysis of 3 Cases.

  2025cites this paper
• Case report: Navigating treatment pathways for cardiac intimal sarcoma with PDGFRβ N666K mutation

  2024cites this paper
• A germline PDGFRB splice site variant associated with infantile myofibromatosis and resistance to imatinib.

  2024cites this paper
• Therapeutic advances of targeting receptor tyrosine kinases in cancer

  2024cites this paper
• Somatic PDGFRB activating variants promote smooth muscle cell phenotype modulation in intracranial fusiform aneurysm

  2024cites this paper
• PDGFRA K385 mutants in myxoid glioneuronal tumors promote receptor dimerization and oncogenic signaling

  2024cites this paper
• Understanding cancer drug resistance with Sleeping Beauty functional genomic screens: Application to MAPK inhibition in cutaneous melanoma

  2023cites this paper
• Corneal Infantile Myofibromatosis Caused by Novel Activating Imatinib-Responsive Variants in PDGFRB

  2023cites this paper
• Corneal Vascularization Associated With a Novel PDGFRB Variant

  2023cites this paper
• Pathogenic mutation hotspots in protein kinase domain structure

  2023cites this paper
• Prenatal genetic diagnosis of disseminated infantile myofibromatosis: a case report and literature review

  2023cites this paper
• Germline Platelet-derived growth factor receptor beta p.R987W pathogenic variant in 2 children with brain tumors

  2023cites this paper
• Genomic analysis reveals germline and somatic PDGFRB variants with clinical implications in familial infantile myofibromatosis

  2023cites this paper
• High-Grade Sarcomas with Myogenic Differentiation Harboring Hotspot PDGFRB Mutations.

  2023cites this paper
• Generalized Infantile Myofibromatosis with Extensive Small Bowel Involvement in a Neonate

  2022cites this paper
• An integrative approach for exploring the nature of fibroepithelial neoplasms

  2022cites this paper
• Novel Oncogenic PDGFRB Variant in Severe Infantile Myofibromatosis With Response to Imatinib Using Therapeutic Drug Monitoring.

  2022cites this paper
• Penttinen syndrome‐associated PDGFRB Val665Ala variant causes aberrant constitutive STAT1 signalling

  2022cites this paper
• Identification of a novel PHIP::BRAF gene fusion in infantile fibrosarcoma

  2022cites this paper
• Avoidance of surgery for head and neck infantile myofibromatosis using imatinib monotherapy

  2022cites this paper
• Segmental overgrowth and aneurysms due to mosaic PDGFRB p.(Tyr562Cys)

  2021cites this paper
• Clinical and molecular response to dasatinib in an adult patient with Penttinen syndrome

  2021cites this paper
• PDGF receptor mutations in human diseases

  2021cites this paper
• Significant Antitumor Activity of Pazopanib in a Patient with PDGFRB-Mutated Metastatic Phyllodes Tumor: a Case Report

  2021cites this paper
• Giant intracranial infantile myofibromatosis of the skull base: report of two cases

  2021cites this paper
• Identification of Early Diagnostic and Prognostic Biomarkers via WGCNA in Stomach Adenocarcinoma

  2021cites this paper
• Aggressive infantile myofibromatosis with intestinal involvement

  2021cites this paper
• Activating variants in PDGFRB result in a spectrum of disorders responsive to imatinib monotherapy

  2020influential citation
• A Distinctive Genomic and Immunohistochemical Profile for NOTCH3 and PDGFRB in Myofibroma With Diagnostic and Therapeutic Implications

  2020cites this paper
• Oncogenic and drug-sensitive RET mutations in human epithelial ovarian cancer

  2020cites this paper
• Kosaki overgrowth syndrome: A novel pathogenic variant in PDGFRB and expansion of the phenotype including cerebrovascular complications

  2020cites this paper
• Genetic testing and surveillance in infantile myofibromatosis: a report from the SIOPE Host Genome Working Group

  2020influential citation
• Solitary adult orbital myofibroma: Report of a case and review of the literature

  2020cites this paper
• A germline mutation in the platelet‐derived growth factor receptor beta gene may be implicated in hereditary progressive mucinous histiocytosis

  2020cites this paper
• Myofibroma/Myofibromatosis

  2020cites this paper
• Pediatric Spindle Cell Tumors

  2019cites this paper
• Spindle Cell Tumors of Adults

  2019cites this paper
• Kosaki overgrowth syndrome: A newly identified entity caused by pathogenic variants in platelet‐derived growth factor receptor‐beta

  2019influential citation
• Novel PDGFRB rearrangement in multifocal infantile myofibromatosis is tumorigenic and sensitive to imatinib

  2019influential citation
• PDGRFB mutation‐associated myofibromatosis: Response to targeted therapy with imatinib

  2019cites this paper
• What is new in pericytomatous, myoid, and myofibroblastic tumors?

  2019cites this paper
• Atomistic mechanism of the constitutive activation of PDGFRA via its transmembrane domain.

  2019cites this paper
• Myopericytomatosis of the Foot: a Case Report Including Molecular Identification of a PDGFRB Mutation

  2019cites this paper
• Naturally occurring and synthetic constitutive-active cytokine receptors in disease and therapy.

  2019cites this paper
• Multiple skin nodules in a newborn

  2019cites this paper
• The role of PDGF-B in brain blood vessels

  2019cites this paper
• Association of PDGFRB Mutations With Pediatric Myofibroma and Myofibromatosis.

  2019cites this paper
• A novel de novo PDGFRB variant in a child with severe cerebral malformations, intracerebral calcifications, and infantile myofibromatosis

  2019cites this paper
• Constitutive activation of the PI3K‐AKT pathway and cardiovascular abnormalities in an individual with Kosaki overgrowth syndrome

  2019cites this paper
• STAT6 Reliably Distinguishes Solitary Fibrous Tumors from Myofibromas

  2018cites this paper
• A rare case of neonatal-onset infantile myofibromatosis with metastatic recurrence in adulthood

  2018cites this paper
• A tyrosine kinase-activating variant Asn666Ser in PDGFRB causes a progeria-like condition in the severe end of Penttinen syndrome

  2018cites this paper
• Effects of Sunitinib and Other Kinase Inhibitors on Cells Harboring a PDGFRB Mutation Associated with Infantile Myofibromatosis

  2018influential citation
• Infantile Myofibromatosis With Intracranial Extradural Involvement and PDGFRB Mutation: A Case Report and Review of the Literature

  2018cites this paper
• Myofibromatosis presenting as reticulated vascular changes and subcutaneous atrophy in a patient with somatic mosaicism of PDGFRB mutation

  2018cites this paper
• Premature Aging Syndrome, Penttinen Type: Report of a Chinese Case with a PDGFRB Mutation.

  2018cites this paper
• Soft tissue tumors occurring in the perinatal/infancy setting: 2nd part

  2018cites this paper
• Heterozygous PDGFRB Mutation in a Three-generation Family with Autosomal Dominant Infantile Myofibromatosis.

  2017cites this paper
• Case report: rapid and durable response to PDGFR targeted therapy in a child with refractory multiple infantile myofibromatosis and a heterozygous germline mutation of the PDGFRB gene

  2017cites this paper
• Myopericytomatosis: Clinicopathologic Analysis of 11 Cases With Molecular Identification of Recurrent PDGFRB Alterations in Myopericytomatosis and Myopericytoma

  2017cites this paper
• Analysis of acquired mutations in transgenes arising in Ba/F3 transformation assays: findings and recommendations

  2017influential citation
• The spectrum of infantile myofibromatosis includes both non-penetrance and adult recurrence.

  2017cites this paper
• Myofibroma in Infancy and Childhood

  2017cites this paper
• Unwanted acquired mutations in Ba/F3 transformation assays

  2017cites this paper
• Recurrent Somatic PDGFRB Mutations in Sporadic Infantile/Solitary Adult Myofibromas But Not in Angioleiomyomas and Myopericytomas

  2017cites this paper
• A patient with germ-line gain-of-function PDGFRB p.N666H mutation and marked clinical response to imatinib

  2017cites this paper
• PDGF‐induced fibroblast growth requires monounsaturated fatty acid production by stearoyl‐CoA desaturase

  2017cites this paper
• The ba/f3 transformation assay: characterization of a novel csf2rb-activating variant, and the discovery of acquired mutations in ba/f3 cells

  2017cites this paper
• Recurrent SRF-RELA Fusions Define a Novel Subset of Cellular Myofibroma/Myopericytoma: A Potential Diagnostic Pitfall With Sarcomas With Myogenic Differentiation

  2017cites this paper
• PDGFRB gain‐of‐function mutations in sporadic infantile myofibromatosis

  2017cites this paper
• STAT1 modulates tissue wasting or overgrowth downstream from PDGFRβ

  2017cites this paper
• INFANTILE MIOFIBROMATOSIS IN NEWBORN: CASE REPORT

  2017cites this paper
• An update on myofibromas and myofibromatosis affecting the oral regions with report of 24 new cases.

  2017cites this paper
• Expansion of the phenotype of Kosaki overgrowth syndrome

  2017influential citation